Study identifies distinct inflammatory signatures in pediatric neurologic disease
Neuroinflammation is a central feature of many pediatric neurologic conditions, yet its precise role has remained difficult to define. A recent study, published in the Journal of Neuroinflammation by researchers at Children’s National Hospital, applies high-sensitivity cerebrospinal fluid (CSF) proteomics to better understand this process across diseases, revealing distinct inflammatory signatures in post-hemorrhagic hydrocephalus (PHH) and anti-NMDA receptor encephalitis (NMDARE).
This collaborative effort brought together experts from the divisions of Critical Care Medicine, Neurosurgery, Neurology and Pathology and Laboratory Medicine, reflecting a multidisciplinary approach to complex pediatric brain disorders. The analysis showed that PHH is associated with a broad, sustained inflammatory response, while NMDARE demonstrates a more targeted immune profile.
Dive deeper
Neuroinflammation has been widely studied in adults, where CSF proteomics has helped identify biomarkers and therapeutic targets. In children, however, progress has been slower due to limited access to CSF samples and less sensitive analytical tools.
To address this gap, researchers used a high-sensitivity, multi-targeted proteomic platform to analyze CSF samples from children with PHH, NMDARE and brain tumor–associated hydrocephalus.
Their findings showed stark differences between conditions. PHH demonstrated a large number of differentially abundant proteins and enrichment of complement, coagulation and platelet-related pathways, pointing to a widespread inflammatory response. NMDARE, in contrast, exhibited a narrower profile, with fewer altered proteins and pathways centered on cytokine signaling and humoral immunity.
What this means
“These findings show that neuroinflammation is disease-specific rather than uniform across pediatric central nervous system (CNS) conditions,” says corresponding author Terry Dean, MD, critical care specialist at Children’s National.
In PHH, the persistence of complement and coagulation pathway activation over weeks suggests these mechanisms may be key drivers of disease progression and potential targets for intervention in a condition that currently lacks medical therapies.
In NMDARE, the identification of B‑cell–related proteins such as IGLC2, MZB1 and CD79B points to promising biomarker candidates. These markers may also extend beyond a single disease, with potential relevance across autoimmune CNS disorders.
How it worked
The study leveraged a pediatric CSF biorepository at Children’s National, enabling access to rare samples and longitudinal data collection.
Using advanced proteomic profiling, researchers analyzed hundreds of inflammation-associated proteins and identified disease-specific patterns through differential expression and pathway analysis.
This approach allowed the team to detect low-abundance inflammatory mediators that may have been missed by earlier techniques, providing a more detailed view of pediatric neuroinflammation.
Why this matters
Sometimes the most important advances come from clarifying how diseases differ at a molecular level. This study shows that pediatric neuroinflammation is not a single process, but a collection of distinct, disease-specific responses.
By identifying persistent inflammatory pathways in PHH and potential biomarkers in NMDARE, the work lays the foundation for more precise diagnostics and targeted therapies. It also highlights the importance of investing in pediatric research infrastructure, such as biorepositories, to enable discovery.
For clinicians and researchers, these insights move the field closer to tailoring treatment based on the underlying biology of each condition, an essential step toward improving outcomes for children with neurologic disease.
Additional authors from Children’s National include: Taylor Broudy, Ankush Bansal, PhD, Akilah Pascall, MD, William Suslovic, Nhu To Chau, Leigh Sepeta, PhD, Courtney Lowe, Shani Israel, Alexandra B. Kornbluh, MD, Claire Marie Har, Hayley Roper, Ilana Kahn, MD, Hasan Syed, MD, Chima Oluigbo, MD, John Myseros, MD, Robert Keating, MD, Elizabeth Wells, MD, MHS, Meghan Delaney, DO, MPH, Daniel Donoho, MD, Kazue Hashimoto-Torii, PhD
Read the full study “Characterizing CSF inflammatory proteomics in pediatric post-hemorrhagic hydrocephalus and Anti-NMDAR encephalitis” in the Journal of Neuroinflammation here.
